WS 007

Drug Profile

WS 007

Alternative Names: WS007

Latest Information Update: 05 Nov 2014

Price : $50

At a glance

  • Originator Waterstone Pharmaceuticals
  • Class Antineoplastics; Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Preclinical Hepatitis B; Hepatitis C

Most Recent Events

  • 05 Nov 2014 Phase-I clinical trials in Cancer in China (unspecified route)
  • 05 Nov 2014 Preclinical trials in Hepatitis C in China (unspecified route)
  • 05 Nov 2014 Preclinical trials in Hepatitis B in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top